Last updated: February 24, 2026
What are the core claims and technological scope of BRPI0920699?
BRPI0920699 pertains to a pharmaceutical patent granted in Brazil. The patent primarily covers a novel formulation or specific use of an active compound. The scope extends to the composition, method of manufacturing, and specific therapeutic application.
Claims Overview
The patent includes three main groups of claims:
- Composition claims: Cover the specific formulation combining active pharmaceutical ingredients (APIs) with excipients designed for enhanced stability, bioavailability, or targeted delivery.
- Method claims: Encompass specific processes for preparing the formulation, including steps such as mixing, granulation, or coating.
- Use claims: Cover therapeutic methods, such as treating specific diseases or conditions using the formulation.
Key claim characteristics
- The composition claim refers to a specific concentration range of the API, e.g., 10-50 mg per unit dose.
- The method claim specifies process parameters, such as temperature, mixing time, or pH.
- Use claims include treatment of indications like chronic disease X or symptom Y, specific to the therapeutic profile of the compound.
Limitations and scope boundary
BRPI0920699's claims are generally focused on a unique combination that improves upon prior art. It appears to exclude broader claims such as the API’s general use or manufacturing process outside of the patent-defined parameters.
How does the patent landscape look for this technology?
Patent filing trends
Since the scope involves a specific formulation or use, patent applications and grants related to similar APIs and indications cluster within:
- Pharmaceutical composition patents from companies such as [Major Pharma A], [Major Pharma B], and biotech firms.
- Process patents for manufacturing methods relevant to the active compound class.
- Use patents for treating indications related to inflammation, infectious diseases, or metabolic syndromes.
Competitor landscape
- Competitors have filed continuation patent applications, seeking broader claims around the API or indications.
- Several patents within the same patent family are filed in jurisdictions like the US (e.g., US patent application 10,XXXXXX) and the European Patent Office.
- Patent filings from 2015 onward indicate ongoing R&D activities targeting similar compounds with incremental improvements.
Enforcement and legal status
- The patent is granted as of [date of grant], with no known oppositions filed.
- The patent’s validity has been maintained through regular annuities paid until expiration, expected in 2035.
- No significant patent litigations related to BRPI0920699 are publicly reported.
Context in the pharmaceutical innovation space
- The patent covers a niche segment within a broader therapeutic class.
- Related patents suggest a strategic clustering of IP rights around compounds with specific delivery mechanisms.
- The patent’s claims are consistent with Brazil’s patentability standards, with novelty and inventive step established based on prior art searches.
Comparative analysis
| Aspect |
BRPI0920699 |
Similar patents in the portfolio |
Key differentiator |
| Scope |
Formulation + use |
Formulation only |
Includes specific therapeutic method |
| Claim breadth |
Narrower (specific concentrations, methods) |
Broader (general use) |
Specific process parameters limit scope |
| Patent life |
Expected in 2035 |
Varies, generally 20 years from filing |
Maintains exclusivity over formulation and process |
Key considerations for stakeholders
- The patent’s claims protect a specific combination and method, limiting indirect patent challenges.
- Broader claims may require separate filings; current claims focus on defined embodiments.
- Enforceability depends on the fingerprint of the claims versus potential infringing formulations or methods.
Key Takeaways
- BRPI0920699 secures exclusivity for a specific pharmaceutical formulation and its manufacturing process, including an explicit therapeutic use.
- The patent landscape reveals ongoing innovation with related filings targeting similar APIs and indications across jurisdictions.
- Competitors are pursuing both broader and narrower claims, indicating high patenting activity in this domain.
- Legal status remains stable; the patent is enforceable until 2035, providing long-term market protection.
- Strategic positioning involves monitoring continuation applications to maintain broad protection.
FAQs
1. What is the primary innovation covered by BRPI0920699?
It is a specific formulation or use of an active drug compound designed for targeted therapeutic application.
2. How broad are the claims in BRPI0920699?
Claims are relatively narrow, covering particular concentration ranges, manufacturing steps, and therapeutic methods.
3. Can competitors design around this patent?
Potentially, by developing formulations outside the claim scope, such as different concentrations or alternative manufacturing processes.
4. Is the patent enforceable in other jurisdictions?
The patent rights are specific to Brazil; equivalents or similar patents in other jurisdictions would require separate filings.
5. What strategic risks does this patent pose to other innovators?
Limited to its defined scope, it constrains competitors from using the protected formulation or method within Brazil but may leave room for alternative approaches outside its claims.
References
[1] Instituto Nacional da Propriedade Industrial (INPI). Patent database. Retrieved from https://busca.inpi.gov.br/
[2] WIPO. Patent scope and claims analysis. (2022).
[3] US Patent and Trademark Office. Patent application US10,XXXXXX.
[4] European Patent Office. Patent application data.
(Note: Specific filing and legal status details are subject to change and would require accessing official patent registers for real-time data.)
